建设单位：宁夏伊品生物科技股份有限公司 建设性质：技术改造 /生物制造产业社群/ 让上下游聚在一起, 未来食农、绿色化工、大健康、美妆个护 等产业同行❤️↓ 项目进展 | 宁夏伊品 【SynBioCon】 获 悉，近日，关于宁夏伊品生物科技股份有限公司精氨酸技术改造项目在相关网 站批复公示。 项目基本情况 项目名称：宁夏伊品生物科技股份有限公司精氨酸技术改造项目 行业类别：C1495食品及饲料添加剂制造 建设地点：本项目位于宁夏回族自治区银川市永宁县杨和镇宁夏伊品生物科技股份有限公司B区内现 有精氨酸生产车间 建设规模： 在现有的L-精氨酸生产线进行技术改造，生产饲料级L-精氨酸，技改后年产L-精氨酸 1.0万吨 建设投资：本项目总投资6551.57万元，环保投资90万元，占总投资的1.37% 建设周期：项目预计2025年6月开工建设，2025年9月竣工试生产，建设期限约为3月 建设内容：本项目利用现有的年产4000吨精氨酸生产线的生产厂房及生产设备进行技术改造，利用 现有发酵设备发酵能力，生产精氨酸。同时购置陶瓷膜、三效结晶器、流化床、自动包装机、码垛机 等设备。 产品方案 | 序号 | 产品名称 | 生产 ...

Core Viewpoint - Zhejiang Huakang Pharmaceutical Co., Ltd. reported a revenue increase of 37.32% in the first half of 2025, driven by the gradual production of new lines in Zhoushan Huakang, despite a slight decline in net profit due to changes in product sales structure and increased financial costs [2][3][14]. Company Overview and Financial Indicators - The company achieved an operating income of approximately 1.87 billion yuan, up from 1.36 billion yuan in the same period last year [2][3]. - Total profit for the period was approximately 150.41 million yuan, a 2.89% increase year-on-year [2][3]. - Net profit attributable to shareholders was approximately 133.71 million yuan, a decrease of 3.38% compared to the previous year [2][3]. - The net cash flow from operating activities was approximately 83.16 million yuan, an increase of 247.72% year-on-year [2][3]. Industry Analysis - The functional sugar alcohol market is projected to reach 7.7 billion USD by 2030, with a compound annual growth rate (CAGR) of about 6.7% [4]. - In China, the production of functional sugar alcohols has shown a stable growth trend, with production expected to exceed 1.89 million tons by 2024, reflecting a 14.49% increase from 2023 [4][5]. - The market size for functional sugar alcohols in China was approximately 10.2 billion yuan in 2022, with expectations to reach 21 billion yuan by 2027 [4][5]. Main Business Overview - The company specializes in the research, production, and sales of various functional sugar alcohols and starch sugar products, including xylitol, sorbitol, maltitol, erythritol, and fructose syrup [8][12]. - The company has established a strong reputation and brand advantage in the sugar alcohol industry, being recognized as a leading manufacturer of xylitol and other sugar alcohols [12][17]. - The company has built a comprehensive sales network covering major domestic and international markets, establishing long-term partnerships with well-known food and beverage companies [12][19]. Competitive Advantages - The company has developed a complete industrial chain around its main products, ensuring stable and sustainable profitability [16][18]. - The company is actively expanding its production capacity and product variety through ongoing projects, such as the 200,000-ton corn deep processing health food ingredient project [14][16]. - The company has a well-experienced management team with a strong understanding of the industry, which enhances its market competitiveness and operational efficiency [19].

Project Overview - The project is named "Jinan Baijie High-Performance New Enzyme Preparation R&D and Industrialization Construction Project" [2] - The construction unit is Jinan Baijie Biological Engineering Co., Ltd., located in the Shanghe Chemical Industry Park, Jinan, covering an area of 70,067.81 m² (approximately 105.1 acres) [2] Investment and Construction Details - The total investment for the project is 775.49 million yuan, with phase one investment at 562.24 million yuan and phase two at 213.25 million yuan [3] - Environmental investment for phase one is 41.59 million yuan (7.39% of total investment), and for phase two is 6.21 million yuan (2.91% of total investment), all funded by the company [3] - The construction period for both phases is 21 months each [4] Production Capacity and Facilities - The project includes the construction of a fermentation workshop with a total of 12 fermentation tanks (6 in each phase), and two extraction and blending workshops [4] - The total production capacity for high-performance new enzyme preparations will be 45,000 tons per annum (t/a), with each phase contributing 22,500 t/a [4] Existing Product Situation - The northern fermentation workshop has been out of production for several years, while the southern workshop is operational [6] - The northern workshop has an annual production capacity of 1,500 tons for α-galactosidase, while the southern workshop has capacities of 5,200 t/a for liquid single enzyme products, 3,000 t/a for liquid proteases, and 8,000 t/a for liquid glucose oxidase and liquid fat enzymes, totaling 17,700 t/a for the entire plant [7] Company Background - Jinan Baijie Biological Engineering Co., Ltd. was formerly known as Jinan Nuoneng Biological Engineering Co., Ltd. and is a wholly-owned subsidiary of Kingsoft Bio-Technology (HK01548), established in 2009 [9] - The company specializes in the R&D, production, and sales of biological enzyme preparations, focusing on feed and industrial enzyme preparations, with core products including glucose oxidase, phytase, and compound enzymes [10]

Project Overview - The project is named "Baikaiseng (Jiangsu) Biotechnology Co., Ltd. New Green Biosynthesis Industrialization Project" with a total investment of 120 million yuan, including 6.13 million yuan for environmental protection [2] - The project will be located in Lianyungang City, Jiangsu Province, covering an area of 29,597 square meters (approximately 44.39 acres) [2] - Construction is planned to start in June 2025 and be completed by December 2025 [2] Production Capacity and Products - The project will establish an automated flexible fermentation production line with a total annual production capacity of: - Squalene: 180 tons - Ergothioneine: 10 tons - Rebaudioside M: 50 tons - Valencene: 20 tons - Ectoine: 40 tons [2][3] - The production lines will operate for varying hours annually, with Squalene production running for 4,728 hours and Ergothioneine for 600 hours [3] Product Applications - Squalene: Used as a dietary supplement to improve fatigue and enhance immunity, suitable for high-pressure or hypoxic environments [5] - Ergothioneine: A natural antioxidant used as a dietary supplement with anti-inflammatory and neuroprotective effects [6] - Ectoine: A natural amino acid derivative with antioxidant and anti-inflammatory properties, aiding in post-exercise recovery [6] - Rebaudioside M: A natural sweetener derived from stevia, approved as a food additive, suitable for various food and beverage applications [6][7] - Valencene: A food additive used to enhance citrus aroma in food products [7] Company Background - Baikaiseng (Jiangsu) Biotechnology Co., Ltd. is a subsidiary of Baikaiseng (Shanghai) Biotechnology Co., Ltd., established on March 15, 2024 [8] - The company focuses on the research and development of biomanufacturing technologies across pharmaceuticals, cosmetics, and food sectors [8]

证券简称： 润普食品 证券代码： 836422 江苏省连云港市灌南县经济开发区（西区） 江苏润普食品科技股份有限公司 江苏润普食品科技股份有限公司招股说明书（申报稿） 本公司的发行申请尚未经中国证监会注册。本招股说明书申报稿不具有据以发行股票的法律效 力，投资者应当以正式公告的招股说明书全文作为投资决定的依据。 本次股票发行后拟在北京证券交易所上市，该市场具有较高的投资风险。北京证券交易所主要 服务创新型中小企业，上市公司具有经营风险高、业绩不稳定、退市风险高等特点，投资者面临较 大的市场风险。投资者应充分了解北京证券交易所市场的投资风险及本公司所披露的风险因素，审 慎作出投资决定。 保荐机构 （济南市市中区经七路 86 号） 1-1-1 中国证监会和北京证券交易所对本次发行所作的任何决定或意见，均不表明其对注册申 请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的盈利能力、 投资价值或者对投资者的收益作出实质性判断或者保证。任何与之相反的声明均属虚假不实 陈述。 根据《证券法》的规定，股票依法发行后，发行人经营与收益的变化，由发行人自行负 责；投资者自主判断发行人的投资价值，自主作出投 ...